Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Roselyne Delepine"'
Autor:
Sophie de Guibert, Thérèse Aurran-Schleinitz, Marie C. Béné, Hervé Maisonneuve, Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Christian Berthou, Florence Cymbalista, Olivier Tournilhac, Stéphane Leprêtre, Eric Van Den Neste, Philippe Rodon, Kamel Laribi, Véronique Leblond, Florence Nguyen-Khac, Rémi Letestu, Pierre Feugier, Caroline Dartigeas, Jean-Pierre Vilque, Alain Delmer, Philippe Colombat, Julie Léger, Beatrice Mahe, Vincent Levy, Roselyne Delepine
Publikováno v:
The Lancet Haematology
The Lancet Haematology, 2018, 5 (2), pp.e82-e94. ⟨10.1016/S2352-3026(17)30235-1⟩
The Lancet Haematology, Elsevier, 2018, 5 (2), pp.e82-e94. ⟨10.1016/S2352-3026(17)30235-1⟩
The Lancet Haematology, 2018, 5 (2), pp.e82-e94. ⟨10.1016/S2352-3026(17)30235-1⟩
The Lancet Haematology, Elsevier, 2018, 5 (2), pp.e82-e94. ⟨10.1016/S2352-3026(17)30235-1⟩
Summary Background Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus observation for elderly patients in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc31e77e3ff43b57d34311d5a749b4b7
https://doi.org/10.1016/s2352-3026(17)30235-1
https://doi.org/10.1016/s2352-3026(17)30235-1
Autor:
Julien Asselineau, Anne Banos, Caroline Bonmati, Romain Guieze, Mario Ojeda-Uribe, Eric Jourdan, Ariane C Mineur, Norbert Ifrah, Arnaud Pigneux, Hacene Zerazhi, Marie C. Béné, Louis-Rachid Salmi, Norbert Vey, Pascale Cornillet-Lefebvre, Marc Bernard, Christian Recher, Eric Delabesse, Jean-Christophe Ianotto, Jean-Yves Cahn, Isabelle Luquet, Roselyne Delepine, Jacques Delaunay, Pierre-Yves Dumas, Yosr Hishri, Luc Fornecker, Mathilde Hunault
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Journal of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Purpose Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, the prospective open-label phase III LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute Myelog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6cda3754c3ce71a68fe4395b73924cb
http://hdl.handle.net/20.500.12278/21453
http://hdl.handle.net/20.500.12278/21453
Autor:
Pierre Feugier, Damien Roos-Weil, Alain Delmer, Florence Nguyen-Khac, Beatrice Mahe, Rémi Letestu, Bruno Cazin, Florence Cymbalista, Marie C. Béné, Olivier Tournilhac, Bernadette Corront, Sandrine Vaudaux, Roselyne Delepine, Stéphane Leprêtre, Véronique Leblond, Bruno Royer, Olivier Casasnovas, Hervé Maisonneuve, Sylvie Chevret, Thérèse Aurran, Eric Van Den Neste
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2018, 103 (7), pp.e304-e306. ⟨10.3324/haematol.2017.183350⟩
Haematologica, 2018, 103 (7), pp.e304-e306. ⟨10.3324/haematol.2017.183350⟩
Haematologica, Vol. 103, no.7, p. e304-e306 (2018)
Haematologica, Ferrata Storti Foundation, 2018, 103 (7), pp.e304-e306. ⟨10.3324/haematol.2017.183350⟩
Haematologica, 2018, 103 (7), pp.e304-e306. ⟨10.3324/haematol.2017.183350⟩
Haematologica, Vol. 103, no.7, p. e304-e306 (2018)
In fit chronic lymphocytic leukemia (CLL) patients without chromosome 17p deletion (del(17p)) or TP53 mutation, six cycles of FCR (fludarabine, cyclophosphamide, rituximab) provides the best progression-free survival (PFS) and overall survival (OS).1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0071adee020c1b6de49dbdf06d596596
https://hal.uca.fr/hal-01860422
https://hal.uca.fr/hal-01860422
Autor:
Thérèse Aurran, Xavier Troussard, Bruno Cazin, Sophie de Guibert, Philippe Colombat, Florence Nguyen-Khac, Hervé Maisonneuve, Marie-Christine Béné, Roselyne Delepine, Elsa Tavernier, Véronique Leblond, Olivier Tournilhac, Florence Cymbalista, Stéphane Leprêtre, Christian Berthou, Caroline Dartigeas, Anne-Sophie Michallet, Pierre Feugier, Marie-Sarah Dilhuydy, Rémi Letestu, Eric Van Den Neste, Vincent Levy, Kamel Laribi, Jean-Pierre Vilque, Alain Delmer
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, 2016, 57 (2), pp.328--334. ⟨10.3109/10428194.2015.1063139⟩
Leukemia & lymphoma, Taylor & Francis, 2016, 57 (2), pp.328--334. ⟨10.3109/10428194.2015.1063139⟩
Leukemia & lymphoma, Taylor & Francis, 2016, 57 (2), pp.328--334. 〈10.3109/10428194.2015.1063139〉
Leukemia & lymphoma, 2016, 57 (2), pp.328--334. ⟨10.3109/10428194.2015.1063139⟩
Leukemia & lymphoma, Taylor & Francis, 2016, 57 (2), pp.328--334. ⟨10.3109/10428194.2015.1063139⟩
Leukemia & lymphoma, Taylor & Francis, 2016, 57 (2), pp.328--334. 〈10.3109/10428194.2015.1063139〉
International audience; Elderly patients with chronic lymphocytic leukemia (CLL) are underrepresented in trials evaluating fludarabine, cyclophosphamide, and rituximab (FCR). We assessed four cycles of FCR with two additional rituximab doses on day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995149bd08c12e89cfaaed5b094e2ef8
https://univ-rennes.hal.science/hal-01272930
https://univ-rennes.hal.science/hal-01272930
Autor:
Claire Quiney, Caroline Dartigeas, Lauren Veronese, Frederic Davi, Loic Ysebaert, Patricia Combes, Brigitte Dreyfus, Laurence Sanhes, Magali Le Garff-Tavernier, Pauline Robbe, Emmanuelle Ferrant, Roselyne Delepine, Anna Schuh, Hélène Merle-Béral, Bruno Pereira, Choquet Sylvain, Pierre Feugier, Florence Nguyen-Khac, Jacques-Olivier Bay, Beatrice Mahe, Olivier Tournilhac, Stéphane Leprêtre, Thérèse Aurran, Alain Delmer, Malgorzata Truchan-Graczyk, Veronique Leblond, Marie-Sarah Dilhuydy, Gian Matteo Pica, Romain Guieze, Sophie de Guibert
Publikováno v:
Blood. 132:3127-3127
Introduction: The 17p deletion (del(17p)) resulting in loss of the TP53 gene is associated with impaired response to genotoxic agents and has an impact on PFS following BTK inhibitor and possibly also venetoclax. The del(17p) usually coincides with T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd745217e90d5264a761dddc01c1e625
https://doi.org/10.1182/blood-2018-99-116722
https://doi.org/10.1182/blood-2018-99-116722
Autor:
Emmanuel Gyan, Christian Berthou, Steven Le Gouill, Philippe Colombat, Roselyne Delepine, Jean-Pierre Vilque, Philippe Quittet, Bernard Desablens, Antoine Thyss, Philippe Bertrand, Eric Deconinck, Jean-François Ramée, Vincent Delwail, Patrick Michenet, Nina Arakelyan, Remi Gressin, Noel Milpied, Jérôme Jaubert, Hervé Maisonneuve, Cécile Moluçon-Chabrot, Charles Foussard
Publikováno v:
Blood
Blood, American Society of Hematology, 2009, 113 (5), pp.995-1001. ⟨10.1182/blood-2008-05-160200⟩
Blood, American Society of Hematology, 2009, 113 (5), pp.995-1001. ⟨10.1182/blood-2008-05-160200⟩
Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cea412c005c886ee7d109ad162875a9
https://doi.org/10.1182/blood-2008-05-160200
https://doi.org/10.1182/blood-2008-05-160200
Autor:
Norbert Vey, Catherine Lacombe, Rachid Salmi, Jean-Yves Cahn, Mario Ojeda, Caroline Bonmati, Thibaut Leguay, Anne Banos, Marc Bernard, Isabelle Luquet, Romain Guieze, François Dreyfus, Eric Jourdan, Roselyne Delepine, Jacques Delaunay, Ariane C Mineur, Marie C. Béné, Bruno Lioure, Jean-Christophe Ianotto, Arnaud Pigneux, Hichri Yosr, Julien Asselineau, Hacene Zerazhi, Norbert Ifrah, Pascale Cornillet-Lefebvre, Christian Recher, Mathilde Hunault
Publikováno v:
Blood
Blood, American Society of Hematology, 2015, 126 (23)
Blood, 2015, 126 (23)
Blood, American Society of Hematology, 2015, 126 (23)
Blood, 2015, 126 (23)
Background: The treatment of Acute Myeloid Leukemia (AML) in elderly patients remains unsatisfactory, with an expected survival time of about 1 year post diagnosis. In an attempt to improve outcome for these patients, the prospective open-label phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d73956c4da8b3b461e79ba478f32840
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01295674
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01295674
Autor:
Philippe Bertrand, Vincent Delwail, Patrick Michenet, Annick Le Pourhiet-Le Mevel, Martine Escoffre-Barbe, Noel Milpied, Antoine Thyss, Remy Gressin, Jean-Pierre Vilque, Eric Legouffe, Bernard Desablens, Roselyne Delepine, Eric Deconinck, Philippe Colombat, Pascale Cornillet-Lefebvre, Jean-François Ramée, Arash Jenabian, Philippe Travade, Charles Foussard, Jérôme Jaubert, Hervé Maisonneuve
Publikováno v:
Blood. 105:3817-3823
Doxorubicin-based immunochemotherapy, with interferon, has been shown to improve survival in patients with advanced follicular lymphoma. High-dose chemotherapy with stem-cell support is effective in follicular lymphoma in relapse but remains controve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ff6125bd9a1b7597e5aa2cb15f6b03
https://doi.org/10.1182/blood-2004-10-3920
https://doi.org/10.1182/blood-2004-10-3920
Autor:
Patrick Mayeux, Roselyne Delepine, Patrice Chevallier, Pierre Bories, T. Lamy, Francois Dreyfus, Norbert Vey, M C Béné, Francis Witz, Cécile Demur, Thomas Prebet, Jerome Tamburini, C. Lacombe, Franck Saint-Marcoux, Nicolas Chapuis, Sophie Park, J.Y. Cahn, Didier Bouscary, Norbert Ifrah, Thibaut Leguay, Annabelle Merlat, Christian Recher
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2013, 27 (7), pp.1479-86. ⟨10.1038/leu.2013.17⟩
Leukemia, 2013, 27 (7), pp.1479-86. ⟨10.1038/leu.2013.17⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2013, 27 (7), pp.1479-86. ⟨10.1038/leu.2013.17⟩
Leukemia, 2013, 27 (7), pp.1479-86. ⟨10.1038/leu.2013.17⟩
International audience; The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf51fd4cb817f6801a9d7edb353d626
https://hal.archives-ouvertes.fr/hal-00849677
https://hal.archives-ouvertes.fr/hal-00849677
Autor:
Pierre Feugier, Frederik Damm, Sophie Raynaud, Xavier Troussard, Julie Lejeune, Nathalie Droin, M'boypa Diop, Sandrine Vaudaux, Roselyne Delepine, Stéphane Leprêtre, Jérôme Lambert, Olivier A. Bernard, Damien Roos-Weil, Claude Lesty, Florence Nguyen-Khac, Vincent Ribrag, Romain Guieze
Publikováno v:
Blood. 128:3202-3202
Introduction Next generation sequencing (NGS) studies have documented the highly heterogeneous landscape of somatic mutations in CLL. Beside the mere genetic diversity of the disease, frequency and clinical impact of mutations vary between analyzed c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54b31cc26e2af1ffe02a107e04efe63f
https://doi.org/10.1182/blood.v128.22.3202.3202
https://doi.org/10.1182/blood.v128.22.3202.3202